Roche and Agilent Technologies Establish Agreement to Provide Continued Service and Support to Roche NimbleGen Microarray Customers
Transition of Services Beginning Immediately
"This global collaboration provides our customers with a confident and straightforward solution to move from NimbleGen to Agilent microarrays," said Dan Zabrowski, Head of Roche Applied Science. "With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect."
"We are working closely with Roche to help customers make the transition to Agilent microarray products," said Robert Schueren, vice president and general manager of Agilent's Genomics Systems Division. "Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond. Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment."
For more information about the transition, visit www.agilent.com/.... For questions relating to service and support of NimbleGen microarray products, call 1-800-227-9770, or email: firstname.lastname@example.org.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,000 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.
For life science research only. Not for use in diagnostic procedures
NIMBLEGEN is a trademark of Roche.
All other product names and trademarks are the property of their respective owners.
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Biotechnik":
Das sind die wichtigsten Techniktrends 2018
In den nächsten zehn Jahren werden fünf Milliarden Anwender über Hochgeschwindigkeitsnetzwerke verbunden sein. Neben Menschen gehen auch Billionen von Maschinen ans Netz. Damit einher geht eine neue Art zu arbeiten. Neue Software treibt die digitale Transformation voran und ermöglicht immer intelligentere Unternehmen.Weiterlesen